Sept 18 (Reuters) - ContraFect Corp :
* CONTRAFECT ANNOUNCES SUBMISSION OF IND APPLICATION TO THE FDA FOR ITS DEVELOPMENT CANDIDATE CF-370
* CONTRAFECT CORP - EXPECT TO INITIATE PHASE 1 FIRST-IN-HUMAN STUDIES IN US LATER THIS YEAR
* CONTRAFECT CORP- FDA WILL REVIEW APPLICATION AND DETERMINE ACCEPTABILITY OF DATA BEFORE CF-370 BEGINS FIRST CLINICAL TRIAL
Source text for Eikon: Further company coverage:
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments